A high-affinity antibody-drug conjugates Actuximab-MMAE for potent and selective targeting of CEACAM5-Positive tumors
Cancer Letters · 2025-06 · 620 · 217685
DOI: 10.1016/j.canlet.2025.217685 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025-06. Verfasst von Yuqi Hu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. Hauptthemen laut MEDLINE: Immunoconjugates, Carcinoembryonic Antigen, Antibodies, Monoclonal, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, Key Technologies Research and Development Program.
Abstract (Originalsprache)
Antibody-drug conjugates (ADCs) represent a promising class of anti-cancer therapy with an increasingly critical role in treating various tumors. They broaden the range of therapeutic targets, enabling the consideration of tumor-associated proteins that are overexpressed but lack well-defined mechanisms. Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is a clinically relevant screening marker due to its tumor-specific overexpression, making it an attractive target for ADC development. However, the therapeutic potential of earlier anti-CEACAM5 ADCs has been limited by side effects and suboptimal drug-to-antibody ratios (DARs), restricting their clinical utility. In this study, we developed a novel anti-CEACAM5 ADC (named Actuximab-MMAE), characterized by high affinity, an optimized DAR, and potent tumor-selective cytotoxicity. Actuximab-MMAE demonstrated rapid and effective elimination of CEACAM5-positive tumors in vivo at low doses, while maintaining a favorable safety profile. These findings highlight Actuximab-MMAE as a promising therapeutic option for CEACAM5-overexpressing tumors, offering a new therapeutic method for targeted cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
- Breast Cancer Center, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, 310022, China.
- Postgraduate Training Base Alliance of Wenzhou Medical University, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
- Hangzhou Institute of Medicine, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, 310018, China.
- Diagnosis and Treatment Center of Breast Diseases, Shantou Central Hospital, Shantou, 515000, China.
- State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, Chi…
Förderung
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- Key Technologies Research and Development Program
- National Key Research and Development Program of China
- Innovative Research Group Project of the National Natural Science Foundation of China
Zitieren
APA
Hu, Y., Du, X., Yuan, J., Gong, X., Zhu, Y., Li, H., Lin, X., Zheng, F., Ran, Y., Na, Z., & Hu, H. (2025). A high-affinity antibody-drug conjugates Actuximab-MMAE for potent and selective targeting of CEACAM5-Positive tumors. Cancer Letters, 620, 217685. https://doi.org/10.1016/j.canlet.2025.217685
Vancouver
Hu Y, Du X, Yuan J, Gong X, Zhu Y, Li H, et al. A high-affinity antibody-drug conjugates Actuximab-MMAE for potent and selective targeting of CEACAM5-Positive tumors. Cancer Letters. 2025;620:217685. doi:10.1016/j.canlet.2025.217685
BibTeX
@article{Hu2025,
author = {Hu, Yuqi and Du, Xin and Yuan, Jiayu and Gong, Xizhao and Zhu, Yue and Li, Hongde and Lin, Xiaorong and Zheng, Fang and Ran, Yuliang and Na, Zhenkun and Hu, Hai},
title = {A high-affinity antibody-drug conjugates Actuximab-MMAE for potent and selective targeting of CEACAM5-Positive tumors},
journal = {Cancer Letters},
year = {2025},
volume = {620},
pages = {217685},
doi = {10.1016/j.canlet.2025.217685}
}
EUVIMED